Healthy subjects and patients with respiratory disease
Conditions
Interventions
In healthy subjects: To collect 10ml of exhaled air using BioScout.
Lung cancer: To collect 10ml of exhaled air using BioScout.
Bronchial asthma: To collect 10ml of exhaled air using BioScout.
C
Sponsors
St. Marianna University School of Medicine Division of Respiratory and Infectious Diseases, Department of Internal Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with expiratory disease a) Lung Cancer: adenocarcinoma, squamous cell carcinoma, small cell carcinoma, large cell carcinoma b) Bronchial asthma: step I to IV c) COPD stage I to IV d) Respiratory infection: pneumonia, pleuritis, pyothorax e) Airway abnormality in systemic disease: sarcoidosis, relapsing polychondritis, wegener granulomatosis
Exclusion criteria
Exclusion criteria: 1) To refuse giving informed consent 2) Lung cancer of unknown histological type 3) Exacerbation within the last 3 months for bronchial asthma 4) Exacerbation within the last 3 months for COPD 5) Unknown bacterias 6) Patients who are pregnant, possibly pregnant, or lactating. 7) Patients with renal failure. (serum creatinine > 2.0 mg/dL, BUN > 30mg/dl) 8) AST or ALT > 100IU 9) Patients with severe diabetes, hyperlipidemia or hyperuricemia 10) Patients who are judged inappropriate by the doctor in charge.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To investigate if IMS can detect and discriminate between volatile organic compounds (VOCs) in patients with respiratory disease including lung cancer, bronchial asthma, COPD, infectious diseases and airway involvement in systemic disease. | — |
Countries
Japan
Contacts
Public ContactHiroshi Handa
St. Marianna University School of Medicine Respiratory and Infectious Diseases, Department of Internal Medicine
Outcome results
None listed